Senshio is indicated for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women.1 The symptoms of vulvovaginal atrophy (VVA) can have a significant impact on a woman’s life.1 Over 60% of post-menopausal women suffer from the symptoms of VVA, such as vaginal dryness and dyspareunia.1-3

Local oestrogens are the mainstay of treatment in moderate to severe VVA – but some women may need another choice:2-5

Senshio® Empowering women through choice [2, 6, 7]

The first oral prescription treatment that does not contain hormones, for post-menopausal women with moderate to severe symptomatic vulvovaginal atrophy (VVA)1,3,8

Local oestrogens are the mainstay of treatment in moderate to severe VVA – but some women may need another choice:2-5

Being able to offer women another choice can enhance discussions and gives you the opportunity to tailor treatment to the individual.2,6,7

    • The first oral, treatment for VVA that does not contain hormones1
    • Works on the underlying cause of VVA to significantly reduce both dyspareunia and vaginal dryness by 12 weeks vs. placebo4
    • With continuous daily use, women can experience benefits by 12 weeks4

Who Is Senshio® For?

Senshio can be used in post-menopausal women with VVA who wish to have choice.

  • Women for whom local oestrogen administration is not an option

Availability of an oral option promotes open conversations about which treatments suit a woman's lifestyle, and what matters to her in terms of administration and convenience2,6

  • Women who are looking for an alternative to hormones

The availability of a hormone-free treatment enables honest discussions with women who are unable or unwilling to use hormones7,13

Some post-menopausal women may also not be candidates for local vaginal oestrogen therapy1

 

Local oestrogen use contraindicated Unable/unwilling to use a local vaginal product

- History of breast cancer

- History of endometriosis or endometrial cancer

- Mild or moderate liver disease or a history of liver disease

- Porphyria

 

- Vaginal prolapse

- Painful to touch

- Concern over cross-contamination

- Dislike messiness

- Cultural sensitivities
Unwilling to use hormones Unable/unwilling Inadequate response from local oestrogen

- Family history of breast cancer

- Safety fears about hormones

- Going through ‘cancer pathway’ has raised fears

- Lack of benefit

- Intolerance to side effects

 

Mechanism of action

Senshio addresses the underlying cause of vulvovaginal atrophy (VVA), helping to regenerate and restore vaginal tissue.2,4,13-15 You can watch the video here

References:

  1. Senshio Summary of Product Characteristics.
  2. Palacios S, Cancelo M. International Journal of Women’s Health 2016; 8: 617–626.
  3. Menopause: diagnosis and management. NICE guideline [NG23] November 2015. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-andmanagement-pdf-1837330217413 [Accessed June 2024].
  4. Bachmann G, et al. Menopause 2010; 17: 480-486.
  5. Nappi, R et al. Minerva Ginecologica 2017; 69(4): 370-80.
  6. Neves-e-Castro M, et al. Maturitas 2015; 81(1): 88–92.
  7. Stuenkel C, et al. JCEM 2015; 100(11): 3975–4011.
  8. Portman D, et al. Maturitas 2014; 78: 91–98.
  9. Kangas L and Unkila M. Steroids 2013; 78(12): 1273-1280.
  10. Pinkerton J and Thomas S. J Steroid Biochem Mol Biol 2014; 142: 142-154.
  11. Del Pup L. Eur Rev Med Pharmacol Sci. 2016; 20(18): 3934-44.
  12. Pérez L. Rev Esp Reumatol 2004; 31(1): 13-7.
  13. Cancelo M, et al. Prog Obstet Ginecol 2016; 59(3): 141-150.
  14. Alvisi S, et al. Gynecol Endocrinol. 2017;33(12):946-950
  15. Nappi R, et al. Climacteric 2015; 18: 233-240
PP-UK-OSP-0349 | July 2024